Vontobel Holding Ltd. Increases Stake in Stryker Corporation $SYK

Vontobel Holding Ltd. lifted its stake in Stryker Corporation (NYSE:SYK) by 301.6% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 94,743 shares of the medical technology company’s stock after purchasing an additional 71,152 shares during the quarter. Vontobel Holding Ltd.’s holdings in Stryker were worth $33,299,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Godfrey Financial Associates Inc. acquired a new position in Stryker in the 4th quarter worth approximately $26,000. United Financial Planning Group LLC acquired a new position in Stryker in the 3rd quarter worth approximately $27,000. DJE Kapital AG acquired a new position in Stryker in the 4th quarter worth approximately $28,000. CGC Financial Services LLC acquired a new position in Stryker in the 4th quarter worth approximately $29,000. Finally, Strive Asset Management LLC acquired a new position in Stryker in the 3rd quarter worth approximately $30,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

Insider Activity at Stryker

In related news, VP Robert S. Fletcher sold 4,544 shares of Stryker stock in a transaction on Thursday, May 28th. The shares were sold at an average price of $306.87, for a total value of $1,394,417.28. Following the sale, the vice president owned 10,582 shares of the company’s stock, valued at approximately $3,247,298.34. This trade represents a 30.04% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP M Kathryn Fink sold 3,500 shares of Stryker stock in a transaction on Monday, May 11th. The shares were sold at an average price of $283.45, for a total transaction of $992,075.00. Following the completion of the sale, the vice president directly owned 177 shares in the company, valued at $50,170.65. This represents a 95.19% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 323,264 shares of company stock valued at $100,659,489. 4.60% of the stock is owned by company insiders.

Analysts Set New Price Targets

SYK has been the topic of several research reports. Truist Financial reiterated a “hold” rating and issued a $330.00 price target (down from $380.00) on shares of Stryker in a report on Monday, May 4th. Wells Fargo & Company cut their price target on shares of Stryker from $456.00 to $418.00 and set an “overweight” rating on the stock in a report on Friday, May 1st. Leerink Partners cut their price target on shares of Stryker from $410.00 to $407.00 and set an “outperform” rating on the stock in a report on Friday, June 5th. Wall Street Zen downgraded shares of Stryker from a “buy” rating to a “hold” rating in a report on Saturday, May 16th. Finally, Sanford C. Bernstein set a $410.00 price objective on shares of Stryker in a research note on Friday, May 1st. Sixteen research analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat, Stryker currently has an average rating of “Moderate Buy” and a consensus target price of $395.33.

Stryker Price Performance

Shares of NYSE SYK opened at $312.14 on Friday. The stock has a market capitalization of $119.66 billion, a price-to-earnings ratio of 36.13, a PEG ratio of 1.93 and a beta of 0.78. Stryker Corporation has a 12 month low of $281.00 and a 12 month high of $404.87. The firm’s 50 day simple moving average is $316.40 and its 200-day simple moving average is $343.97. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.11 and a quick ratio of 1.25.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Thursday, April 30th. The medical technology company reported $2.60 EPS for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). The firm had revenue of $6.02 billion for the quarter, compared to analyst estimates of $6.34 billion. Stryker had a return on equity of 23.42% and a net margin of 13.20%.Stryker’s revenue for the quarter was up 2.6% compared to the same quarter last year. During the same period in the previous year, the business earned $2.84 EPS. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Analysts expect that Stryker Corporation will post 14.98 EPS for the current year.

Stryker Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Tuesday, June 30th will be paid a $0.88 dividend. The ex-dividend date of this dividend is Tuesday, June 30th. This represents a $3.52 dividend on an annualized basis and a yield of 1.1%. Stryker’s dividend payout ratio (DPR) is currently 40.74%.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.